KI

Kolinpharma SpAMIL Kolinpharma Stock Report

Last reporting period 31 Dec, 2022

Updated —

Last price

Market cap $B

0.011

Micro

Exchange

XMIL - Borsa Italiana S.P.A.

KIP.MI Stock Analysis

KI

Uncovered

Kolinpharma SpA is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

44/100

Low score

Market cap $B

0.011

Dividend yield

Shares outstanding

1.623 B

Kolinpharma SpA engages in the research, development, and marketing of food supplements based on natural raw materials of natural origin. The company is headquartered in Lainate, Milano and currently employs 110 full-time employees. The company went IPO on 2018-03-09. The firm offers a number of products, including almetax, which is a food supplement based on alpha-lipoic acid, L-tryptophan, turmeric, vitamins B5, b6 AND C, Chromium picolinade and Zinc that acts synergistically on the main symptoms of menopause; Almatex easy, which enables the preservation of the general well-being of the body; Dolasix, which is a food supplement that acts synergistically in favor of the normal functionality of cartilages and connective tissues; Ivuxur, which is a food supplement based on cranberry ( dried cranberry extract), D-mannose, bearberry and Zinc that is used in the treatment of unary tract infections; Milesax, which is a food supplement based on magnesium bisglycinate, boswellia serrata and L-tryptophan that acts synergistically on contractures, muscles relaxation and mood during the rehabilitation and recovery phases, and Xinepa, among others.

View Section: Eyestock Rating